Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
The company’s official launch comes five months after major investors such as Atlas Venture and Bain Capital filed a Shanghai stock exchange filing for a biotech named “Hercules CM NewCo.” ...
Threatened with sanctions and loss of its agreement with Medicare and Medicaid, J&J is rolling back a plan to give hospitals after-the-fact rebates for 340B drugs.
Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a ...
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
Cheong points to the broad spectrum of patient demographics in the APAC region for creating substantial opportunities for clinical trial sponsors who are keen to meet enrolment targets at an expedited ...
Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.
The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
Solventum, formerly 3M Health Care, announced today the launch of the 3M™ Harvest RC Centrate Chromatographic Clarifier, a ...